Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy of malignant melanoma.

× No keyword cloud information.

46 in total

1. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.

Authors: D L Ahmann; R G Hahn; H F Bisel; R T Eagan; J H Edmonson
Journal: Cancer Chemother Rep Date: 1975 Mar-Apr

Review 2. Chemotherapy of malignant melanoma.

Authors: J K Luce
Journal: Cancer Date: 1972-12 Impact factor: 6.860

3. Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma.

Authors: W J Sieper; M J Mastrangelo; R E Belle
Journal: Cancer Chemother Rep Date: 1975 Nov-Dec

4. Treatment of metastatic melanoma with combined 5-fluorouracil and procarbazine.

Authors: E M Nordman; M Mäntylä
Journal: Cancer Treat Rep Date: 1977-12

5. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.

Authors: R E Wittes; W K Hong; L Gatchell; I H Krakoff; R B Golbey
Journal: Oncology Date: 1977 Impact factor: 2.935

6. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.

Authors: D L Ahmann; H F Bisel; J H Edmonson; R G Hahn; R T Eagan; M J O'Connell; S Frytak
Journal: Clin Pharmacol Ther Date: 1976-06 Impact factor: 6.875

7. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.

Authors: G Beretta; G Bonadonna; N Cascinelli; A Morabito; U Veronesi
Journal: Cancer Treat Rep Date: 1976-01

8. [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].

Authors: U R Kleeberg; W Schreml
Journal: Dtsch Med Wochenschr Date: 1976-06-04 Impact factor: 0.628

9. Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.

Authors: S M Cohen; E M Greenspan; L H Ratner; M J Weiner
Journal: Cancer Date: 1977-01 Impact factor: 6.860

10. Phase 2 study with Baker's Antifol in solid tumors.

Authors: V Rodriguez; S P Richman; R S Benjamin; M A Burgess; W K Murphy; M Valdivieso; R L Banner; J U Gutterman; G P Bodey; E J Freireich
Journal: Cancer Res Date: 1977-04 Impact factor: 12.701

2 in total

1. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.

Authors: D A Amato; H Bruckner; D Guerry; A Ash; G Falkson; E C Borden; R H Creech; E D Savlov; T J Cunningham
Journal: Invest New Drugs Date: 1987 Impact factor: 3.850

2. The evolution in melanoma treatment as a reflection of precision-oriented medicine.

Authors: Igal Kushnir; Ofer Merimsky
Journal: Oncol Lett Date: 2012-12-05 Impact factor: 2.967

2 in total